# US 2021/0277006 A1 · Crystalline salts of 5-methyl-(6s)-tetrahydrofolic acid and amino ethyl esters

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277006 A1
- Document ID: US20210277006A1
- Status: Published application
- Kind: A1
- Application number: 17/258,040
- Filed: 2019-07-02
- Published: 2021-09-09
- Earliest claimed: 2018-07-06
- Assignees: Merck Patent GmbH
- Applicants: Merck Patent GmbH
- Inventors: Rudolf MOSER; Viola GROEHN; Ruth BOEHNI STAMM; Fritz BLATTER; Martin SZELAGIEWICZ
- Web page: https://patentgrep.com/patent/US20210277006A1

## CPC

- C07D 475/04: with a nitrogen atom directly attached in position 2
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 19/10: for osteoporosis
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07C 229/36: with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester like L-phenylalanine ethyl ester or L-methionine ethyl ester, wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to amino acid ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

## Claims

### Claim 1

A crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to amino acid ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof.

### Claim 2 (depends on 1)

The crystalline salt of claim 1, wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to the amino acid ethyl ester is from 1:0.5 to 1:2.5 (in mol/mol) and/or hydrates and/or solvates thereof.

### Claim 3 (depends on 1)

The crystalline salt of claim 1, wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to the amino acid ethyl ester is from 1:0.75 to 1:2.25 (in mol/mol) and/or hydrates and/or solvates thereof.

### Claim 4 (depends on 1)

The crystalline salt of claim 1, wherein the ratio of 5-methyl-(6S)-tetrahydrofolic acid to the amino acid ethyl ester is approximately 1:1 (in mol/mol) and/or hydrates and/or solvates thereof.

### Claim 5 (depends on 1)

The crystalline salt of claim 1, wherein the ratio of 5-methyl-(6S)-tetrahydrofolic acid to the amino acid ethyl ester is approximately 1:2 (in mol/mol) and/or hydrates and/or solvates thereof.

### Claim 6 (depends on 1)

The crystalline salt of claim 1, wherein the amino acid ethyl ester is L-phenylalanine ethyl ester and the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to L-phenylalanine ethyl ester is from 1:1.75 to 1:2.25 (in mol/mol) and/or hydrates and/or solvates thereof.

### Claim 7 (depends on 1)

The crystalline salt of claim 1, wherein the amino acid ethyl ester is L-phenylalanine ethyl ester and the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to L-phenylalanine ethyl ester is approximately 1:2 (in mol/mol) and/or hydrates and/or solvates thereof.

### Claim 8 (depends on 1)

The crystalline salt of claim 1, characterized in that the salt is the salt of 5-methyl-(6S)-tetrahydrofolic acid and L-phenylalanine ethyl ester and has a PXRD pattern with at least one characteristic peak (expressed in 2θ±0.2° 2θ (CuKα radiation)) selected from the following peaks located at 4.0, 6.4, 15.0, 15.9, 17.1, 18.4, 18.6, 21.9, 22.6, and 25.5 (Form A).

### Claim 9 (depends on 1)

The crystalline salt of claim 1, characterized in that the salt is the salt of 5-methyl-(6S)-tetrahydrofolic acid and L-phenylalanine ethyl ester and has a PXRD pattern with at least one characteristic peak (expressed in 2θ±0.2° 2θ (CuKα radiation)) selected from the following peaks located at 4.0, 6.4, 7.3, 7.9, 12.5, 13.5, 13.9, 14.3, 15.0, 15.9, 17.1, 17.4, 17.9, 18.2, 18.4, 18.6, 20.1, 21.1, 21.9, 22.6, 24.3 and 25.5 (Form A).

### Claim 10 (depends on 1)

The crystalline salt of claim 1, characterized in that the salt is the salt of 5-methyl-(6S)-tetrahydrofolic acid and L-phenylalanine ethyl ester and has a PXRD pattern substantially as shown in FIG. 1 (Form A).

### Claim at position 11 (depends on 1)

The crystalline salt of claim 1, characterized in that the salt is the salt of 5-methyl-(6S)-tetrahydrofolic acid and L-phenylalanine ethyl ester and has a PXRD pattern with at least one characteristic peak (expressed in 2θ±0.2° 2θ (CuKα radiation)) selected from the following peaks located at 3.7, 6.8, 7.5, 13.2, 14.9, 17.8 and 18.3 (Form B).

### Claim 12 (depends on 1)

The crystalline salt of claim 1, characterized in that the salt is the salt of 5-methyl-(6S)-tetrahydrofolic acid and L-phenylalanine ethyl ester and has a PXRD pattern with at least one characteristic peak (expressed in 2θ±0.2° 2θ (CuKα radiation)) selected from the following peaks located at 3.7, 6.8, 7.5, 13.2, 14.9, 15.7, 16.2, 17.8, 18.3, 18.6, 19.0, 19.2, 19.5, 19.7, 21.3, 23.2, 23.6, 25.4 and 25.9 (Form B).

### Claim 13 (depends on 1)

The crystalline salt of claim 1, characterized in that the salt is the salt of 5-methyl-(6S)-tetrahydrofolic acid and L-phenylalanine ethyl ester and has a PXRD pattern substantially as shown in FIG. 2 (Form B).

### Claim 14 (depends on 1)

The crystalline salt of claim 1, wherein the amino acid ethyl ester is L-methionine ethyl ester and the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to L-methionine ethyl ester is from 1:0.75 to 1:1.25 (in mol/mol) and/or hydrates and/or solvates thereof.

### Claim 15 (depends on 1)

The crystalline salt of claim 1, wherein the amino acid ethyl ester is L-methionine ethyl ester and the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to L-methionine ethyl ester is approximately 1:1 (in mol/mol) and/or hydrates and/or solvates thereof.

### Claim 16 (depends on 1)

The crystalline salt of claim 1, characterized in that the salt is the salt of 5-methyl-(6S)-tetrahydrofolic acid and L-methionine ethyl ester and has a PXRD pattern with at least one characteristic peak (expressed in 2θ±0.2° 2θ (CuKα radiation)) selected from the following peaks located at 5.5, 7.0, 8.5, 14.0, 14.7, and 17.7 (Form A).

### Claim 17 (depends on 1)

The crystalline salt of claim 1, characterized in that the salt is the salt of 5-methyl-(6S)-tetrahydrofolic acid and L-methionine ethyl ester and has a PXRD pattern with at least one characteristic peak (expressed in 2θ±0.2° 2θ (CuKα radiation)) selected from the following peaks located at 3.5, 5.5, 7.0, 8.5, 13.2, 14.0, 14.7, 17.7, 18.4, 21.6, 23.0, 23.9, and 27.6 (Form A).

### Claim 18 (depends on 1)

The crystalline salt of claim 1, characterized in that the salt is the salt of 5-methyl-(6S)-tetrahydrofolic acid and L-methionine ethyl ester and has a PXRD pattern substantially as shown in FIG. 4 (Form A).

### Claim 19 (depends on 1)

The crystalline salt of claim 1, characterized in that the salt is the salt of 5-methyl-(6S)-tetrahydrofolic acid and L-methionine ethyl ester and has a PXRD pattern with at least one characteristic peak (expressed in 20θ±0.2° 2θ (CuKα radiation)) selected from the following peaks located at 7.3, 14.0, 14.7, 15.7, and 18.3 (Form B).

### Claim 20 (depends on 1)

The crystalline salt of claim 1, characterized in that the salt is the salt of 5-methyl-(6S)-tetrahydrofolic acid and L-methionine ethyl ester and has a PXRD pattern with at least one characteristic peak (expressed in 2θ±0.2° 2θ (CuKα radiation)) selected from the following peaks located at 5.0, 7.3, 8.5, 10.2, 13.8, 14.0, 14.7, 15.7, 18.3, 18.7, 20.5, 20.9, 22.2, 24.1, and 24.5 (Form B).

### Claim 21 (depends on 1)

The crystalline salt of claim 1, characterized in that the salt is the salt of 5-methyl-(6S)-tetrahydrofolic acid and L-methionine ethyl ester and has a PXRD pattern substantially as shown in FIG. 5 (Form B).

### Claim 22 (depends on 1)

A process for obtaining the crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester according to claim 1 comprising the steps of:
i) providing a mixture of 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester, optionally in a suitable solvent or a mixture of solvents
ii) adding a base, optionally in a suitable solvent or a mixture of solvents;
iii) heating the composition to at least 60° C. and optionally carrying out a clear filtration;
iv) crystallizing and cooling the mixture to a temperature between 1° C. and 30° C., optionally adding more solvent or mixture of solvents; and
v) isolating the obtained solid material and optionally drying the product.

### Claim 23 (depends on 22)

The process of claim 22, characterized in that the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and the amino acid ethyl ester in step i) is in the range of from 1:1 to 1:3.

### Claim 24 (depends on 22)

The process of claim 22, characterized in that the solvent is water.

### Claim 25 (depends on 22)

The process of claim 22, characterized in that in step iii) and/or iv) seed crystals are added.

### Claim 26 (depends on 22)

The process of claim 22, characterized in that the amino acid ethyl ester is L-phenylalanine ethyl ester or L-methionine ethyl ester.

### Claim 27 (depends on 26)

The process of claim 26, characterized in that L-phenylalanine ethyl ester or L-methionine ethyl ester is added as hydrochloride.

### Claim 28 (depends on 1)

A pharmaceutical composition, food additive and/or preparation comprising the crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester selected according to claim 1 and optionally one or more acceptable excipients.

### Claim 29 (depends on 28)

The pharmaceutical composition according to claim 28 in the form of tablets, capsules, oral liquid preparations, powders, lyophilisates, granules, lozenges, reconstitutable powders, injectable or infusable solutions or suspensions or suppositories.

### Claim 30 (depends on 28)

The pharmaceutical composition according to claim 28 further comprising at least one additional therapeutic agent.

### Claim 31 (depends on 28)

The pharmaceutical composition according to claim 28, which is a pharmaceutical composition for oral, parenteral, intramuscular, intraspinal, intrathecal, peridontal, topical or rectal administration.

### Claim 32 (depends on 28)

The pharmaceutical composition according to claim 28, characterized in that the amino acid ethyl ester is L-phenylalanine ethyl ester or L-methionine ethyl ester.

### Claim 33 (depends on 1)

A method for producing a drug or a food comprising incorporating a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester according to claim 1 in the drug or food.

### Claim 34 (depends on 33)

The method according to claim 33, characterized in that the amino acid ethyl ester is L-phenylalanine ethyl ester or L-methionine ethyl ester.

### Claim 35 (depends on 1)

A method comprising administering a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester according to claim 1 in a treatment for homocysteine-lowering, or for a treatment of anemia, neural tube defects, cardiovascular diseases, depression, cognitive impairment, Alzheimer's disease and osteoporosis and/or dietary management of low plasma and/or low red blood cell and/or low cerebrospinal fluid and/or low peripheral or central nervous system folate.

### Claim 36 (depends on 35)

The method according to claim 35, characterized in that the amino acid ethyl ester is L-phenylalanine ethyl ester or L-methionine ethyl ester.

### Claim 37 (depends on 1)

The crystalline salt of claim 1 having at least 99 wt % or more chemical and/or stereoisomerical purity
